GUSS GRIMMETT: Open Payments
NPI 1881620730 · BLACKFOOT, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$723 in 50 payments from 15 companies in 2025. Trend: 2023 $487 · 2024 $677 · 2025 $723
Food & beverage: $723
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $267 |
| Axsome Therapeutics, Inc. | 4 | $63 |
| Lilly USA, LLC | 4 | $63 |
| Insulet Corporation | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $30 |
| Novo Nordisk Inc | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
Products named: VRAYLAR, QULIPTA, Auvelity, Omnipod, MOUNJARO, LEQVIO, VOQUEZNA, TRELEGY ELLIPTA.
Industry payments across ID — which companies pay providers there.
